Stay updated with breaking news from Continuous Commitment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of life…
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained reductions
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis remain